Mulder H, Franke B, van der-Beek van der A Aart, Arends J, Wilmink F W, Egberts A C G, Scheffer H
Department of Clinical Pharmacoepidemiology, Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Pharmacogenomics J. 2007 Oct;7(5):318-24. doi: 10.1038/sj.tpj.6500422. Epub 2006 Oct 3.
The use of antipsychotics is associated with an increased risk of obesity. This consideration makes it important to search for determinants that can predict the risk for antipsychotic-induced obesity. In this cross-sectional study, we investigated whether polymorphisms in the HTR2C gene were associated with obesity (body mass index >30 kg/m2) in patients using antipsychotics. We examined polymorphisms in the promoter region of the HTR2C gene ((HTR2C:c.1-142948(GT)n, rs3813928 (-997 G/A), rs3813929 (-759 C/T), rs518147 (-697 G/C)) and an intragenic polymorphism (rs1414334:C>G). The results of the logistic regression were expressed as adjusted odds ratios (OR). In total, we included 127 patients mainly diagnosed with schizophrenia or schizoaffective disorder (89%). The results indicate that a combined genotype carrying the variant HTR2C:c.1-142948(GT)n 13 repeat allele, the common allele rs3813929 C, the variant allele rs518147 C and the variant allele rs1414334 C is significantly related to an increased risk of obesity (OR 3.71 (95% confidence interval: 1.24-11.12)).
使用抗精神病药物与肥胖风险增加相关。鉴于此,寻找能够预测抗精神病药物所致肥胖风险的决定因素就显得尤为重要。在这项横断面研究中,我们调查了使用抗精神病药物的患者中,HTR2C基因多态性是否与肥胖(体重指数>30kg/m²)相关。我们检测了HTR2C基因启动子区域的多态性((HTR2C:c.1 - 142948(GT)n, rs3813928 (-997 G/A), rs3813929 (-759 C/T), rs518147 (-697 G/C)))以及一个基因内多态性(rs1414334:C>G)。逻辑回归结果以调整后的比值比(OR)表示。我们总共纳入了127例主要诊断为精神分裂症或分裂情感性障碍的患者(89%)。结果表明,携带变异型HTR2C:c.1 - 142948(GT)n 13重复等位基因、常见等位基因rs3813929 C、变异等位基因rs518147 C和变异等位基因rs1414334 C的联合基因型与肥胖风险增加显著相关(OR 3.71(95%置信区间:1.24 - 11.12))。